AstraZeneca PLC Block listing Interim Review (3770V)
02 Dicembre 2019 - 4:00PM
UK Regulatory
TIDMAZN
RNS Number : 3770V
AstraZeneca PLC
02 December 2019
02 December 2019 15:00 GMT
Block Listing Six Monthly Return
Information provided on this form must be typed or printed
electronically and provided to an ris.
Date: 2 December 2019
Name of applicant: ASTRAZENECA PLC
Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE
OPTION PLAN; ASTRAZENECA
ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED
SHARE OPTION SCHEME
------------------------------------------------------------------
Period of return: From: 1 June 2019 To: 30 November 2019
----------------------- ------------------------- ------------- ------------------------
Balance of unallotted securities under scheme(s)
from previous return: 1,248,036
------------------------------------------------------------------
Plus: The amount by which the block scheme(s) has
been increased since the date of the last
return (if any increase has been applied for): 0
------------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 136,370
------------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period: 1,111,666
------------------------------------------------------------------
Name of contact: CAMILLA JOHNSTONE
Telephone number of contact: 020 3749 5000
------------------
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal and Metabolism, and Respiratory.
AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711
BioPharmaceuticals (Renal) Environmental, Social and
Nick Stone Governance +44 203 749 5716
BioPharmaceuticals (Respiratory)
Josie Afolabi Other medicines +44 203 749 5631
Finance
Craig Marks Fixed income +44 7881 615 764
Corporate access
Jennifer Kretzmann Retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BLRFSEFLEFUSEDE
(END) Dow Jones Newswires
December 02, 2019 10:00 ET (15:00 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024